Introduction
The Myb proto-oncogene was first identified as the cellular homolog of two replication-defective acute transforming avian retroviruses, AMV and E26, that cause myeloblastic and erythroblastic leukemias (Radke et al., 1982; Oh and Reddy, 1999) . Expression of c-Myb is predominantly associated with immature hematopoietic cells. In each hematopoietic lineage, expression of c-Myb is highest at the immature stages of differentiation and downregulation of c-Myb is associated with hematopoietic maturation (Graf, 1992) . This pattern of c-Myb expression suggests that it plays an important role during hematopoietic maturation, and this has been supported in several model systems. Most significantly, mice that lack a functional Myb locus die by day 15 of embryonic development due to a defect in determinant erythropoiesis (Mucenski et al., 1991) . Recently, experiments using tissue-specific expression of a dominant interfering Myb protein, chimeras made with Rag1 À/À blastocysts and Myb-null embryonic stem cells and tissue-specific ablation at the Myb locus have provided insight into roles for c-Myb during hematopoiesis (Badiani et al., 1994; Allen et al., 1999; Emambokus et al., 2003; Bender et al., 2004) . While these experiments provide insight into c-Myb function during normal hematopoiesis, relatively little is understood about the downstream effectors of c-Myb activity.
The v-and c-Myb proteins are nuclear, DNA-binding phosphoproteins that function as transcription activators (Lipsick, 1996) . Three distinct functional domains have been identified on c-Myb: a DNA-binding domain (DBD), a transactivation domain (TA) and a negative regulatory domain (NRD) (Oh and Reddy, 1999) . The c-Myb DBD is located at the amino-terminus and is a highly conserved region consisting of three tandem repeats of approximately 50 amino acids each (R1, R2 and R3). Vertebrates possess two additional genes that are closely related to Myb, Mybl1 (encoding A-Myb) and Mybl2 (encoding B-Myb) (Nomura et al., 1988) . While all three mammalian Myb proteins can bind the consensus c-Myb DNA-binding sequence, they have distinct tissue and cell type patterns of expression. A-Myb is highly expressed in male germ cells, female breast ductal epithelium and subsets of B lymphocytes (Golay et al., 1996) , while B-Myb expression appears to be ubiquitous (Nomura et al., 1988; Golay et al., 1991; Reiss et al., 1991) . Expression of c-Myb is predominantly detected in normal tissue and tumor cells of hematopoietic origin, with the highest levels of Myb mRNA expression occurring in immature cells (Westin et al., 1982) .
Several approaches have been used to identify Mybregulated genes. First, several v-Myb target genes were identified via differential screening of myeloid cell lines transformed by a temperature-sensitive v-Myb protein or an estrogen-inducible version of v-Myb, including mim-1 (Ness et al., 1989) and tom-1 (Burk et al., 1997) . However, it is unclear if these genes play a role in mediating v-Myb transformation of myeloid cells. Second, several candidate c-Myb-regulated genes have been identified based on the presence of Myb consensus DNA-binding sequences in the 5 0 flanking regions including genes encoding c-kit (Ratajczak et al., 1998) , human CD34 , CD13/aminopeptidase N (Shapiro, 1995) , human oxytocin receptor (Inoue et al., 1994) , murine neutrophil elastase (Oelgeschlager et al., 1996; Nuchprayoon et al., 1997) , mouse CD4 (Siu et al., 1992) , c-Myc (Evans et al., 1990; Schmidt et al., 2000) and N-Ras (Ganter and Lipsick, 1997) , although in some cases little evidence has been presented demonstrating the ability of c-Myb to regulate expression of the endogenous locus. Finally, microarray assays have been used to identify potential c-Myb target promoters in models based on forced expression of Myb family members or a dominant interfering Myb protein (Rushton et al., 2003; Lang et al., 2005) . While several of these target genes provide insight into the regulation of transcription by c-Myb, little is understood about how c-Myb can maintain hematopoietic cell proliferation and suppress terminal differentiation.
Studies of potential c-Myb target promoters have demonstrated that c-Myb activity can be modulated by interaction with other transcription factors and coactivators as well as post-translational modifications (Oh and Reddy, 1999) . For example, c-Myb activates mim-1, GBX-2 and tom-1 by cooperating with members of the C/EBP transcription factor family (Ness et al., 1993; Burk et al., 1997) , which are highly expressed in myelomonocytic cells. The coactivator p100 has been reported to directly interact with the c-Myb DBD and regulate c-Myb-dependent transcription transactivation (Leverson et al., 1998) . In addition, Ets family members have also been identified as binding partners that act in cooperation with c-Myb. Interestingly, c-Myb has been reported to activate transcription of several promoters by a mechanism that does not require direct interaction between c-Myb and DNA via the DBD. For example, cMyb and heat shock transcription factor 3 (HSF3) interact via their DBDs and activate transcription from the hsp70 promoter via heat shock elements but in the absence of consensus Myb-binding sites (Kanei-Ishii et al., 1997) . c-Myb activity can also be suppressed by direct interactions between c-Myb and other proteins such as p160/p67, ATBF1, Cyp-40 and c-Maf (Ness, 1999) . More recently, it has been reported that c-Myb can physically interact with GATA-1 using in vitro binding assays and that c-Myb and GATA-1 each is able to suppress the transcription transactivating activity of the other on two synthetic promoters (Takahashi et al., 2000) . Thus, depending on the promoter context, multiple protein interactions determine the ability of cMyb to regulate gene expression and may explain the ability of c-Myb to regulate some genes in a tissuespecific manner while regulating other genes in multiple hematopoietic lineages.
Friend virus-infected mouse erythroleukemia (MEL) cell lines provide an early erythroid precursor model system that can be induced to terminally differentiate with chemical agents such as HMBA in cell culture (Friend et al., 1971; Marks and Rifkind, 1978) . Expression of c-Myb is downregulated during MEL cell differentiation, and forced expression of c-Myb blocks chemically induced MEL cell differentiation (McClinton et al., 1990) . To gain insight into the mechanism of cMyb-regulated differentiation in MEL cells, we developed C19 MEL cell lines that carry an inducible dominant interfering Myb protein (MEnT) and induction of MEnT expression provides a sufficient signal for MEL cells to differentiate (Chen et al., 2002) . We now identify the carbonic anhydrase I erythroid-specific promoter (CAIe) as a target of c-Myb activity. We demonstrate that Myb activity is required for CAIe promoter activity in MEL cells, that c-Myb and GATA-1 physically interact with the CAIe promoter in vivo and in vitro and that c-Myb and GATA-1 act synergistically to activate transcription from the CAIe promoter. Interestingly, forced expression of CAI inhibited HMBA-induced differentiation in C19 MEL cells and maintained them in a proliferating state. Thus, CAI appears to be a downstream mediator of c-Myb activity in regulating MEL cell proliferation and differentiation.
Results
Identification of carbonic anhydrase I (CAI) as a potential myb-regulated gene C19 MEL cells are transformed erythroid precursors that can be induced to differentiate with chemical agents including DMSO and HMBA (Friend et al., 1971; Marks et al., 1987) . c-Myb is downregulated during HMBA induced differentiation and forced expression of c-Myb can block differentiation (Gonda and Metcalf, 1984; Marks et al., 1987; Clarke et al., 1988; McClinton et al., 1990) . To develop a model that would allow the identification of Myb target genes, we have generated stable transfectants in the C19 MEL cell line that carry a dominant interfering Myb transgene (MEnT). MEnT consists of the mouse c-Myb DBD fused to the transcription suppression domain of the Drosophila Engrailed protein (Badiani et al., 1994) . Expression of MEnT in these stable transfectants is regulated by the ZnCl 2 -inducible mouse metallothionein I (MTH-I) promoter and induced expression of MEnT in C19 MEL cells provides a sufficient signal to induce differentiation (Chen et al., 2002) . One of these transfectants, clone 17, was grown in culture for 4, 24 and 72 h with or without ZnCl 2 and total cellular RNA from each sample was analysed by differential display. Potential Myb target genes were identified as cDNA fragments detected in parental C19 MEL cells, or in clone 17 cells grown in the absence of ZnCl 2 but not after inducing expression of MEnT. Figure 1a presents a portion of a differential display gel, the arrow indicating a cDNA species (G5-1) that was not detected after treatment of clone 17 cells with ZnCl 2 for 24 and 72 h.
A portion of the gel containing the G5-1 fragment identified in Figure 1b was excised, the fragment eluted from the gel and subjected to a second round of PCR, using the same primers previously used for differential display. The reamplified PCR fragment was used to synthesize a probe for Northern blotting experiments to compare mRNA expression in C19 MEL cells treated with HMBA and clone 17 cells treated with ZnCl 2 . As expected, after the addition of HMBA to C19 MEL cells, expression of Myb mRNA decreased in a biphasic manner as the cells differentiated ( Figure 1b , lanes 1-7, middle panel). The G5-1 fragment hybridized with a single mRNA species of approximately 1.5 kb. Expression of the 1.5 kb mRNA species began to decrease at 24 h and was barely detectable by 48 h in C19 MEL cells treated with HMBA ( Figure 1b, top panel) . In clone 17 cells, adding ZnCl 2 resulted in MEnT expression by 4 h, and decreased expression of the G5-1-hybridizing mRNA species was apparent between 4 and 24 h ( Figure 1b, lanes 8-14) . In C19 MEL cells treated with HMBA and clone 17 cells treated with ZnCl 2 , expression of the 1.5 kb mRNA species was decreased >90 and 80% respectively by 120 h post-treatment with ZnCl 2 . Downregulation of the G5-1-hybridizing mRNA species in the presence of MEnT appeared to be more rapid The DNA sequence of the reamplified G5-1 cDNA fragment was obtained and found to be identical to the 3 0 untranslated region of the mouse CAI cDNA (Fraser and Curtis, 1986) . Carbonic anhydrases (CA) catalyse the reversible hydration of CO 2 and play a critical role in cellular diffusion of CO 2 , ion transport, pH regulation and modulation of hemoglobin O 2 affinity (Henry, 1996) . The primary sites of CAI expression are colonic epithelium and erythroid cells (Tashian, 1989) . Previous work demonstrated that transcription of CAI was downregulated during C19 MEL cell differentiation induced with DMSO (Fraser and Curtis, 1987) , suggesting that regulation of CAI expression may be related to the differentiation process in MEL cells. The pattern of CAI expression, as measured using the full-length CAI cDNA to probe the filter used in Figure 1b , was identical to that of G5-1 (data not shown).
CAIe function is dependent on Myb activity in MEL cells
The locus encoding the CAI isozyme is unusual among the CA in that it has two cell type-specific promoters separated by a 36 kb intron (Fraser et al., 1989; Lowe et al., 1990; Brady et al., 1991) . The two promoters act in a mutually exclusive manner (Sowden et al., 1993) , the proximal promoter drives CAI mRNA expression in the colonic epithelium while the distal promoter functions to direct transcription of CAI in developing erythroid cells. The coding region of the mRNAs transcribed from these two promoters is identical but the erythroid mRNA contains a short (63 and 72 bp in mouse and human, respectively) 5 0 noncoding exon that replaces part of the 5 0 untranslated region of the colonic CAI mRNA (Fraser et al., 1989; Brady et al., 1991) . Examination of the mouse CAIe promoter sequence revealed three potential Myb-binding sites at positions À203 to À198, À130 to À124 and À123 to À119 (Figure 2 ). We carried out chromatin immunoprecipitation (ChIP) assays to determine if c-Myb binds to the CAIe promoter in vivo. C19 MEL cells were fixed with formaldehyde to crosslink proteins and DNA that are in close proximity. Subsequently, the cells were lysed and the crosslinked chromatin was sheared by sonication. The soluble, fragmented chromatin was immunoprecipitated with antibodies specific to c-Myb or control antibodies. After reversal of the crosslinking, immunoprecipitated DNA was purified and subjected to PCR analysis using primers specific for CAIe promoter. As presented in Figure 3 , immunoprecipitation of chromatin with anti-c-Myb antibody specifically enriched for endogenous CAIe promoter DNA but not with preimmune serum or no antibody. In addition, immunoprecipitation with anti-c-Myb antibodies did not enrich for cyclin G2 promoter DNA, which lacks c-Mybbinding sites (Figure 3) . Thus, c-Myb is able to bind the CAIe promoter in C19 MEL cells in vivo.
To determine if sequence elements in the CAIe promoter are required for Myb-mediated regulation of CAIe expression, the mouse erythroid-specific CAI (CAIe) promoter reported by Fraser et al. (1989) was isolated from genomic DNA by PCR and placed immediately upstream of the luciferase-coding sequences in the pGL3.Basic promoterless expression plasmid in both the sense and antisense orientations to generate pGL3.CAIe-s and pGL3.CAIe-as, respectively. These plasmids were tested for promoter activity in C19 MEL cells. Transient transfection of pGL3.CAIe-s into C19 MEL cells resulted in a dose-dependent increase of luciferase activity 15-20-fold higher than the activity observed with the promoterless reporter pGL3.Basic, while the pGL3.CAIe-as did not result in increased luciferase activity relative to pGL3.Basic (Figure 4 ). To Figure 2 Nucleotide sequence of the mouse CAIe. The CAIe promoter sequence is presented (Fraser and Curtis, 1986) and is GenBank accession number M28196. Nucleotide positions are numbered from the transcription start site, which is marked by an arrow. The first exon of the mouse erythroid form of CAI mRNA is indicated by capital letters. Potential DNA-binding sites for cMyb and GATA proteins are underlined and shaded, respectively. Chromatin proteins were crosslinked to DNA by formaldehyde in intact MEL cells and immunoprecipitated with antibodies specific for c-Myb or GATA-1, preimmune serum or no antibody. The precipitated DNA samples were either undiluted or diluted to 1:2 and 1:4 and amplified by PCR with CAIe-and Cyclin G2 (G2)-specific primers. PCR products were fractionated in agarose gels, transferred to nylon membranes and visualized using 32 P-labelledspecific DNA probes. The positive control is representative of 1% of total input chromatin used in the immuoprecipitation step. The data are representative of four independent experiments. determine if expression from pGL3.CAIe was dependent on Myb activity in MEL cells, we transiently transfected clone 17 cells with pGL3.CAIe-s. Expression of luciferase activity from pGL3.CAIe-s in clone 17 cells in the absence of ZnCl 2 was similar to C19 MEL cells. However, ZnCl 2 treatment of clone 17 cells to induce MEnT expression resulted in dramatically decreased CAI promoter activity to basal levels. ZnCl 2 treatment of parental C19 MEL cells had a modest, nonspecific suppressive effect on luciferase expression, with a maximum decrease in luciferase activity of 1.5-2-fold. We detect the same, nonspecific suppression of luciferase activity by ZnCl 2 in C19 MEL cells or clone 17 cells using multiple promoter/reporter constructs in the presence of ZnCl 2 (data not shown). However, CAIe promoter activity was reduced greater than 17-fold in clone 17 cells treated with ZnCl 2 . Thus, we conclude that CAIe promoter activity is dependent on Myb activity in C19 MEL cells.
c-Myb and GATA-1 act to synergistically activate transcription from the CAIe promoter The ability of c-Myb to regulate CAIe promoter activity was evaluated by transient co-transfection of the CAIe promoter/reporter vector with a c-Myb expression vector in CV1 cells, which contain little endogenous cMyb activity (Figure 5a ). pGL2.CAIe-s had little activity above background in CV1 cells. Cotransfection of the c-Myb expression vector pRMB.3SV with the pGL2.CAIe-s promoter reporter into CV1 cells resulted in a modest 1.5-2-fold increase in luciferase activity compared to the pGL2.CAIe-s alone. We reasoned that weak transactivation of the CAIe promoter by c-Myb in CV-1 cells could be due to the absence of a transcription coactivator that is normally expressed in C19 MEL cells but is absent in CV1 cells. Thus, it was of interest that GATA-like motifs have previously been identified in the human CAIe promoter region and are conserved in the mouse CAIe promoter (Brady et al., 1989) as presented in Figure 2 . Previous reports identified a specific DNAbinding complex using a fragment from the human CAIe promoter containing the GATA-like motifs in electrophoretic mobility shift assays (EMSAs) when the fragment was incubated with protein extracts from erythroid cells but not from non-erythroid cells (Sowden et al., 1993) , and we find that GATA-1 protein associates with the CAIe promoter by ChIP assay in C19 MEL cells in vivo (Figure 3 ).
The ability of GATA proteins to activate transcription from the CAIe promoter has not been previously tested, so we carried out experiments to determine if cMyb can cooperate with members of the GATA family of transcription factors to direct transcription from the CAIe promoter. Cotransfection of 0.1 mg of the pEF.-GATA1 expression vector with pGL2.CAIe-s resulted in a modest five-fold increase in luciferase activity over background, and increasing the amount of GATA-1 expression vector slightly decreased the promoter activity ( Figure 5a ). However, cotransfection of both c-Myb and GATA-1 expression vectors with pGL2.CAIe-s resulted in more than a 25-fold activation of the CAIe promoter. We also observed the synergistic activation of the CAIe promoter by c-Myb and GATA-1 in other cell lines that do not express detectable amounts of c-Myb or GATA-1, including CMT-COS and 293T cells (data not shown). Importantly, the synergistic transactivation of the CAIe promoter by cMyb and GATA-1 was promoter-specific, as indicated by the lack of transcriptional upregulation with two Bars indicate the average luciferase activity normalized with respect to protein concentrations. Luciferase activity of the reporter gene in the absence of exogenous transactivator was designated as one. The average promoter activities were generated from five independent experiments carried out in duplicate. Error bars indicate standard deviation of the mean. (b) CV1 cells were transfected with 0.1 mg of either the pGL2CAIe-s reporter construct, an IL-2 promoter/reporter construct or an EF1apro-moter/reporter construct and vectors for c-Myb and GATA-1 expression as indicated below the columns. The bars indicate the average luciferase activity normalized with respect to protein concentrations. The luciferase activity of the reporter gene in the absence of exogenous transactivator was designated as one. The average promoter activities were generated from three independent experiments carried out in duplicate. Error bars indicate standard deviation of the mean.
Carbonic anhydrase I promoter is a c-Myb target J Chen et al independent promoter/reporter constructs (pGL2.IL2 and pGL2.EF1a), demonstrating that the increased transcriptional activity from the CAIe promoter was not due to a general increase in transcription resulting from forced expression of c-Myb and GATA-1 (Figure 5b) . Furthermore, the synergistic activation of the CAIe promoter appeared to be specific for the combination c-Myb and GATA-1, as cotransfection of c-Myb and GATA-2 resulted in a 5-6-fold increase of promoter activity, similar to that seen with GATA-1 alone (data not shown). Similarly, B-Myb, which is expressed in MEL cells and CV-1 cells, did not activate transcription from the CAIe promoter in either the presence or absence of GATA-1 (Figure 5a ). We conclude that the synergistic activation of the CAIe promoter in these experiments is a specific effect of a functional interaction between c-Myb and GATA-1. Furthermore, these results strongly suggest that the CAIe promoter is a target of c-Myb, but not B-Myb activity.
CAIe promoter requirements for synergistic transactivtion by c-Myb and GATA-1 To better define the DNA sequence requirements for the synergistic activation of the CAIe promoter by c-Myb and GATA-1, we constructed a series of nested 5 0 deletions of the CAIe promoter (MutC, MutF and MutG in Figure 6a ). Deletions up to position À111 (MutC and MutF), which eliminated all three putative c-Myb-binding sites and retained only one GATAbinding site at À69, had no significant effect on the synergistic increase of transcription activity from the CAIe promoter observed in the presence of c-Myb and GATA-1. Only after deleting up to position À61 (MutG), which also deletes the GATA binding site A at À69, is the synergistic activation of transcription by cMyb and GATA-1 abolished. A small internal deletion that removes the TATA box from the CAIe promoter (T-del) also abolished the enhanced promoter activity due to cotransfection of c-Myb and GATA-1. These results suggested that the GATA binding site A at À71 to À64, or its flanking region, was required for synergistic activation of the CAIe promoter by c-Myb and GATA-1. To determine if the GATA site A or regions flanking the GATA site A were important for the synergistic activation of transcription from the CAIe promoter by c-Myb and GATA-1, additional mutations were built and tested by cotransfection assay. Deletion of the GATA site A at position À71 to À64 in MutF to create DGATA(A) (Figure 6a and b) resulted in only a modest decrease in transcription activity from the CAIe promoter in the presence of c-Myb and GATA-1, indicating that the 40 bp from position -111 to -72 upstream of the GATA site A were responsible for mediating the synergistic transactivation of CAIe in the presence of c-Myb and GATA-1 (Figure 6b and c) . To further characterize the DNA sequences required for synergistic activation of CAIe by c-Myb and GATA-1, 10 bp substitution mutations scanning this 40 bp region were introduced in the context of the DGATA(A) promoter/reporter construct (Figure 6b and c). Each 10 bp in the fragment was substituted by the sequence TGCTCGAGCC, which contains no Myb-or GATA-binding sites. Transient cotransfection of the linker scanning mutants with c-Myb and GATA-1 expression vectors into CV1 cells revealed that the LS3 and LS4 mutants could still be synergistically transactivated by GATA-1 and c-Myb (Figure 6c ). In contrast, the LS1 and LS2 mutations abrogated the synergistic activation resulting from cotransfection with c-Myb and GATA-1. Thus, the DNA sequences required for the synergistic activation of the CAIe promoter by c-Myb and GATA-1 are included in the 20 bp that were substituted by the LS1 and LS2 mutations.
We performed EMSAs using nuclear extracts from C19 MEL cells to determine if c-Myb or GATA-1 can bind to a synthetic oligonucleotide (oligo CA1) that contains the CAIe promoter sequence from À111 to À71 (Figures 6b and 7a , lane 1). Two major complexes (CI and CII) with retarded mobility were detected in C19 MEL cell nuclear extracts. The presence of GATA-1 protein in the slower migrating CI complex was demonstrated by a complete supershift with an anti-GATA-1 monoclonal antibody (Figure 7a, lane 4) . The presence of c-Myb protein in both complexes was supported by two pieces of evidence. First, incubation of the nuclear extract with the anti-c-Myb monoclonal antibody 5E resulted in inhibition of both complexes ( Figure 7a, lane 2) . A control monoclonal antibody, which reacts with the human 9E10 c-Myc epitope, did not have any effect on formation of the CI or CII complexes (Figure 7a, lane 3) . Second, the presence of cMyb in both complexes was supported by cold competition experiments where the CI and CII complexes were both effectively competed by incubation with unlabeled probe oligo CA1 (Figure 7a, lanes 5-7) or an unlabeled oligonucleotide containing a single mim-1A Myb-binding site (MRE, Figure 7a, lanes 2-4) . In contrast, an unrelated oligonucleotide did not efficiently compete for DNA binding with CI and CII (NS, Figure 7a , lane 8). These results strongly suggest that c-Myb and GATA-1 are contained in a complex, or complexes, that interact with this region of the CAIe promoter. In agreement with the transient transfection results using the linker scanning mutants, an unlabeled oligonucleotide probe that contained the promoter sequence defined by LS3 and LS4 (CA4, À111 to À92, Figure 6b ) did not compete for binding to CI or CII (Figure 7b, lanes 3-5) , while an oligonucleotide containing the CAIe promoter sequence spanning LS1 and LS2 (CA5, À91 to À72, Figure 6b ) competed both complexes away as efficiently as the unlabeled full-length probe (compare Figure 7b , lanes 6-8 with lanes 9-11). We note two GATA-like sequences in this 20 bp region that resemble the consensus GATA motif. These results demonstrate that a complex, or complexes, containing cMyb and GATA-1 is able to interact with the CAIe promoter at positions À91 to À72 and suggest that this complex(es) is required for the synergistic increase in transcription transactivation of the CAIe induced by c-Myb and GATA-1.
CAI can modulate differentiation and proliferation of C19 MEL cells It has been clear for some time that c-Myb plays a crucial role in regulating proliferation and differentiation in MEL cells. However, little is understood about the downstream effectors of c-Myb activity. Since our results demonstrate that Myb activity is crucial for CAIe promoter function in C19 MEL cells, we wished to determine if CAI mediated any of the downstream effects of c-Myb, at least in part, in regulating C19 MEL cell proliferation and differentiation. For this purpose, we made stable transfectants in C19 MEL cells carrying a mouse CAI transgene with the carboxyl-terminus tagged by the 9E10 human c-Myc epitope tag. The constructs were built in pMTH.neo, which contains a mouse metallothionein I promoter to provide for potential inducible expression in response to treatment with ZnCl 2 (Cuddihy et al., 1993) . However, the stable transfectants that we isolated were leaky and addition of ZnCl 2 to the growth medium resulted in only a three-to fourfold increase in expression of the CAI transgene over untreated stable transfectants (Figure 8a ). The amount of exogenous CAI produced by the stable transfectants was sufficient to maintain total CAI levels after treatment with HMBA at 1.5-2-fold greater than the undifferentiated parental C19 MEL cell line. The experiments described below were carried out in the presence of ZnCl 2 but identical results were obtained in either the presence or absence of ZnCl 2 .
The CAI stable transfectants did not have altered rates of proliferation (see below) or survival (data not shown) relative to the parental C19 MEL cells or empty vector stable transfectants nor did they display evidence of spontaneous differentiation. To determine if downregulation of CAI expression is important during differentiation of C19 MEL cells, we measured the appearance of hemoglobin-producing cells by acidbenzidine staining in the CAI stable transfectants, empty vector transfectants and parental C19 MEL cells during a 5-day time course of differentiation in response to HMBA. As presented in Figure 8b , treatment of C19 MEL cells or empty vector control transfectants resulted in the appearance of acid-benzidine-positive cells by 48 h post treatment with HMBA. This number continued to increase over the 5-day time course and reached 80-83% by day 5 after treatment with HMBA. In contrast, exogenous expression of CAIe in clone4-1(S) cells resulted in a nearly 70% decrease in the number of hemoglobin-producing cells detected 2 days after treatment with HMBA and a greater than 50% reduction in hemoglobin-producing cells was detected by day 3. Inhibition of differentiation in clone 4-1(S) cells, as measured by acid-benzidine staining, continued to be apparent throughout the remainder of the differentiation assay. Comparable results were consistently obtained with multiple independent clones. Thus, modulation of CAI expression is able to alter the rate of differentiation after treatment with HMBA in C19 MEL cells.
A second aspect of HMBA-induced differentiation in MEL cells is decreased proliferation that begins between days 2 and 3 after treatment with HMBA. To determine if modulating CAI expression during differentiation altered proliferation of C19 MEL cells, we compared proliferation of clone 4-1(S) with the parental C19 MEL cell line and an empty vector control stable transfectant in the presence or absence of HMBA by counting viable cell numbers. As presented in Figure 8c , ectopic overexpression of CAI protein in clone 4-1(S) did not alter proliferation in logarithmically growing C19 MEL cells as compared to the empty vector stable transfectant or parental C19 MEL cells. When differentiation was induced in the empty vector stable transfectant or the parental C19 cell line, proliferation began to decrease between days 2 and 3 after treatment with HMBA, which is consistent with numerous previous reports Lipsick, 1996) . However, in contrast, we found little decrease in proliferation of the clone 4-1(S) stable transfectant cells in response to HMBA, suggesting that maintenance of CAI expression is associated with a proliferating state in C19 MEL cells. Again, equivalent results were consistently obtained with multiple, independent clones. Thus, maintaining CAI expression during HMBA-induced differentiation in C19 MEL cells is able to modulate both the rate of differentiation and proliferation. Figure 2 . Each transfection contained a total of 0.4 mg of plasmid DNA. The average promoter activities were generated from three independent experiments carried out in duplicate. Error bars indicate standard deviation of the mean. (b) Partial DNA sequence of the wild-type and linker scan replacement reporter plasmids. The wild-type sequence of CAIe from À111 to À52 is shown at the top. DGATA(A) is constructed from MutF with deletion of the seven bases composing the GATA site A-binding site. Linker scanning mutations LS1 through LS4 were constructed from DGATA(A). CA1, CA4 and CA5 identify the positions of oligonucleotides used for EMSA experiments presented in Figure 7a and b. (c) Wild-type and mutated promoter/reporter constructs, listed at left, were transfected into CV1 cells as described above. The average promoter activities were generated from three independent experiments carried out in duplicate. Error bars indicate standard deviation of the mean.
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Discussion
Abundant experimental evidence supports the notion that c-Myb is a key regulator of hematopoietic cell growth and differentiation. However, while a number of potential targets of c-Myb activity have been described, understanding how the downstream effects of c-Myb are mediated is still limited. We have developed a model system to address this question using MEL cells that express a dominant interfering Myb protein under the control of an inducible promoter. Expression of MEnT provides a sufficient signal to induce terminal differ- Clone 4-1(S), C19 MEL cells or empty vector transfectants were cultured with 3 mM HMBA and 100 mM ZnCl 2 for a 5-day period. The proportion of cells staining acid-benzidine positive was counted on successive days. Values were generated from three independent experiments. Error bars indicate standard deviation of the mean. (c) Deregulated expression of CAI modulates proliferation in C19 MEL cells. Clone 4-1(S) and empty vector stable transfectants were plated at 10 5 cells/ml in growth medium containing 100 mM ZnCl 2 and 3 mM HMBA. Viable cell numbers were determined on successive days. Histograms were generated from three independent experiments. Error bars indicate standard deviation of the mean. -12) . Unlabeled oligonucleotides containing a single mim-1A Myb responsive element (MRE, lanes 6-8), CA1 (lanes 9-11) or a nonspecific oligonucleotide (lane 12) were added to the binding reactions in a 10 to 100 molar excess as indicated. (b) Localization of protein/DNA interactions on the À111/À71 CAIe promoter fragment. C19 MEL nuclear extracts were mixed with 32 P-end-labeled oligo CA1 and either unlabeled oligonucleotide CA4 (À111 to À91), oligonucleotide CA5 (À90 to À71) or a nonspecific oligonucleotide competitor. Nucleotide sequences of the CA1, CA4 and CA5 oligonucleotides are presented in Figure 6b . entiation in C19 MEL cells and these cells provide a useful system to identify physiologically relevant c-Myb target promoters (Chen et al., 2002) . Our experiments using this model have identified the CAIe promoter, which is downregulated during MEL cell differentiation, as a potential target of c-Myb activity. Previous studies have demonstrated that transcription from the CAIe promoter and steady-state CAI mRNA levels are decreased during differentiation of C19 MEL cells, induced to differentiate with DMSO (Fraser and Curtis, 1987) . However, the mechanism that regulates CAI expression and the physiological significance of CAI downregulation in relation to MEL cell differentiation are not well understood. We have demonstrated that cMyb interacts with the CAIe promoter in vivo and that expression of CAI not only decreased during HMBAinduced differentiation of C19 MEL cells but was also downregulated in the presence of MEnT, suggesting that expression of CAI is dependent on Myb activity in MEL cells. Furthermore, when the CAIe promoter region was fused with the luciferase reporter gene and transiently transfected into C19 MEL cells, strong promoter activity was observed compared to the promoterless control vector, and this promoter activity was strongly inhibited in the presence of MEnT, providing further support that Myb activity is essential for expression of CAI in MEL cells.
Previous studies identified several GATA-like DNAbinding motifs in the CAIe region and when a fragment from the promoter containing the GATA motifs was placed upstream of a minimal eukaryotic promoter it directed transcription in erythroid progenitor cells but not in non-erythroid cells (Brady et al., 1989) . These experiments suggested that GATA proteins might be required for transcription from CAIe. (Kirsch et al., 1986) . In contrast, GATA-1 expression is not downregulated during C19 MEL cell differentiation, nor is its DNA-binding activity decreased (J Chen and TP Bender, unpublished data; Busfield et al., 1995) . CAI transcription is downregulated, but not completely turned off, when C19 MEL cells are induced to differentiate, suggesting that GATA-1 by itself may be responsible for maintaining the low level of CAI expression in differentiated C19 MEL cells. This notion is supported by the modest fivefold increase in transcription from the CAIe promoter in the presence of GATA-1 relative to the promoter alone in CV-1 cells.
The CAIe promoter region contains three consensus Myb-binding sites and a purified c-Myb DBD was in fact able to bind to these sites when tested in EMSA (data not shown). However, our results demonstrated that the Myb-binding sites in the CAIe promoter region were dispensable for c-Myb-and GATA-1-mediated coactivation. We narrowed down the CAIe promoter sequence to a minimal 20 bp region that is sufficient to mediate the synergistic activation by c-Myb and GATA-1. Two GATA-like motifs exist in this region, one at À86 to À82, and the other on the complementary strand at positions À77 to À73. Although these sequences are different from the consensus GATA-binding site, our EMSA experiments provide strong evidence that both cMyb and GATA-1 are contained in a complex, or complexes, that interact with this 20 bp sequence in C19 MEL cell nuclear extracts, suggesting that c-Myb may bind to this region through an interaction with GATA-1 protein. This is similar to activation of the human Hsp70 promoter by c-Myb and HSP3, where c-Myb and HSP3 form an active complex that acts via heat shock elements but does not require a Myb-binding site for activity (Kanei-Ishii et al., 1997) . Thus, it is of interest that cMyb and GATA-1 have been reported to interact via their DBDs in vitro and we are able to coimmunoprecipitate c-Myb and GATA-1 from cell lines (J Chen and TP Bender, unpublished data). While our results suggest that c-Myb and GATA-1 can act synergistically to transactivate the CAIe promoter by binding to GATAlike motifs, in the context of chromosomal DNA, c-Myb that is contained in a complex on the 20 bp sequence described in this manuscript may still interact with the other consensus Myb-binding sites located in the CAIe promoter, potentially providing increased stability for complex binding.
The dominant interfering Myb protein (MEnT) used in these studies was built by fusing the transcription repressor domain of Drosphila engrailed to a truncated c-Myb DBD (Badiani et al., 1994) . It therefore has the DNA-binding potential of c-Myb. However, the other two members of the vertebrate Myb family, A-Myb and B-Myb, are highly homologous to c-Myb in the DBD and they appear to bind DNA in a similar fashion. MEnT most likely will inhibit transcription from genes regulated by one or more Myb family members. Thus, we were interested to determine if B-Myb, which is also expressed in MEL cells, could activate CAIe. A-Myb is not expressed in C19 MEL cells (J Chen and TP Bender, unpublished data). To address this question, we compared the ability of c-Myb and B-Myb to activate expression of CAIe by transient cotransfection assay. In contrast to cMyb, we found that B-Myb alone or in combination with GATA-1 failed to activate the transcription from the CAIe promoter in transient transfection assays (Figure 5a ), suggesting that regulation of the CAIe promoter is a function of c-Myb and GATA-1, but not B-Myb. However, it remains possible that B-Myb may transactivate the CAIe promoter in other cellular contexts.
While work reported in this manuscript is the first demonstration of a functional interaction between c-Myb and GATA-1 on a natural promoter, others have reported physical and functional interactions between these proteins in vitro and on synthetic promoters. Takahashi et al. (2000) reported that c-Myb and GATA-1 interact in vitro via their DBDs using a GST-pull down assay and that these proteins could reciprocally inhibit each other's activities on synthetic promoters. It was proposed that this inhibitory effect could be due to the exclusive binding characteristics of !c-Myb and GATA-1 to CBP. In contrast, our findings demonstrate that c-Myb and GATA-1 can synergize on at least some promoters. These seemingly opposing findings can be reconciled in several ways. First, it is likely that interaction between c-Myb and GATA-1 may simply have different effects on different promoters since interaction between c-Myb and GATA-1 might result in different outcomes depending on promoter context. Second, Takahashi et al. (2000) used two synthetic promoter fragments, one containing six tandem repeats of the Myb-binding site and the other representing a minimal GATA-1 promoter. These synthetic promoters may not reflect situations on natural promoters where Myb-and GATA-binding sites are located in the same promoter, or when they function via novel DNA sequences. Third, differences in experimental conditions may account for these seemingly contradictory results. Takahashi and co-workers transfected relatively large amounts of DNA (more than 15 mg), while we used relatively small amounts of DNA (0.4 mg DNA) in our transfections. Transfection of large amounts of DNA may have toxic effects on cells, or it may have a nonspecific effect on transcription by squelching.
CA catalyse the reversible hydration of CO 2 and are key regulators of acid base homeostasis in mammals (Henry, 1996) . Our results demonstrate that overexpression of CAI in C19 MEL cells delayed HMBA-induced differentiation. The products of CO 2 hydration, H þ and HCO 3 À , are transported to the extracellular environment via Na þ /H þ and Cl -/HCO 3 -ion exchangers to maintain a stable intracellular pH. In our C19 MEL cell CAI stable transfectants, overexpression of CAI resulted in two-to fourfold increase in the level of CAI protein compared to wild-type or the empty vector-transfected control C19 MEL cells. Thus, the CAI stable transfectants contain a greater amount of CA activity that may result in increased production of H þ from CO 2 hydration, resulting in decreased intracellular pH and increased transport of H þ across the plasma membrane via the Na þ /H þ ion exchanger. Increased transport of H þ could result in decreased extracellular pH. Interestingly, changes in extracellular pH have been reported to affect erythroid differentiation by several groups. Endo et al. (1994) observed both higher spontaneous and induced differentiation in the human erythroid precursor cell lines KU-812 and K562 cultured at pH 7.6 than when cultured at lower pH values. Similarly, it has been reported that peripheral blood CD34 þ progenitor cells cultured at high (7.6) pH contained greater numbers of hemoglobin-positive and band-3-positive cells, and acquired these erythroid differentiation markers sooner than cultures grown at standard (7.35) and low (7.1) pH (Mcadams et al., 1998) . Analysis of CD71 and CD45RA expression by flow cytometry also indicated that erythroid differentiation proceeded faster at high pH and was blocked at an intermediate stage by low pH. Thus, the altered rates of differentiation that we observe in our CAI stable transfectants relative to C19 MEL cells may be due in part to changes in extracellular pH due to the different amounts of CAI protein expression. In support of this notion, it is of interest to consider reports that extracellular pH in solid tumors is more acidic than in adjacent normal tissue, and that acidification of the extracellular environment of malignant tumors may increase the invasive behavior of cancer cells (Webb et al., 1999; Cardone et al., 2005) . For example, it has been reported that human melanoma cells cultured in acidic growth medium have a greater invasive potential than when tested in medium at standard pH (Martinez-Zaguilan et al., 1996) . Interestingly, several CA isozymes are overexpressed in a variety of tumor types and may be functionally related to oncogenesis (Martinez-Zaguilan et al., 1996; Liao et al., 1997; Tureci et al., 1998; Pastorekova et al., 2004; Cardone et al., 2005) . Indeed, the carbonic anhydrase inhibitor acetazolamide can inhibit the invasive potential of cancer cells in vitro, apparently by inhibiting cell proliferation and consequently reducing the number of cells capable of invasion (Parkkila et al., 2000) . Together, these results suggest that CA isozymes may play a significant role in favoring deregulated proliferation of tumor cells, as well as a metastatic phenotype. The development of specific inhibitors for CA isozymes may provide novel therapeutic agents for some types of cancer.
Avian erythroblastosis virus (AEV)-transformed erythroleukemia cells are blocked in differentiation by two oncogenes v-ErbA and v-ErbB (Beug et al., 1996) . Erythroblasts that are transformed with AEV will grow in vitro over a considerable range of pH and salt concentrations and are blocked at an immature stage of erythroid differentiation. v-Erb-B alone is able to transform avian erythroblasts but these cells have a limited tolerance to pH and salt concentrations in the growth medium and a portion of the cells spontaneously differentiate. v-Erb-A alone has little, if any, capacity to transform erythroblasts. However, v-Erb-A is able to confer pH and salt tolerance to v-Erb-B-transformed erythroblasts and appears to prevent their spontaneous differentiation. v-ErbA is postulated to contribute to erythroleukemia by repression of erythroid-specific genes (Zenke et al., 1988; Disela et al., 1991; ) , which include CAII and Band 3 (erythrocyte H þ /Na þ exchanger) (Ciana et al., 1998) . Both CAII and Band 3 are expressed at low levels in primary avian erythroblasts and are not detectable in MEL cells. In each case, expression greatly increases after differentiation. v-ErbA binds to an enhancer region of CAII, resulting in repression of CAII expression. GATA-1-binding sites were also identified in this enhancer region and it was suggested that v-ErbA prevents the activation of CAII by neutralizing in cis the activity of GATA-1 in undifferentiated cells (Beug et al., 1996) . When the contribution of CAII and Band 3 to the leukemic phenotype was tested by superinfecting v-Erb-B/Atransformed cells with viruses encoding either CAII or Band3 (Fuerstenberg et al., 1992) , clones were readily derived with Band 3 viruses and these had more restricted pH and salt requirements but did not differentiate. However, only two colonies were obtained with CAII-expressing viruses and it was suggested that high CAII levels were toxic. The two colonies that were isolated had narrow tolerance for pH and salt but were not differentiated. Since few colonies were available to study that carried the transduced CAII, it is likely that the two colonies that did manage to grow had compensated to some degree for the high level of CAII expression. However, it is clear that simply reintroducing CAII did not overcome the block to differentiation (Fuerstenberg et al., 1992) . If CAI and CAII were simply redundant proteins, it might be surprising to find that CAII expression is suppressed in AEV-transformed erythroblasts. However, CAI and CAII differ in several ways. First, CAI and CAII are both expressed in erythrocytes but expression is very tightly regulated during differentiation of both normal and transformed erythroblasts (Tashian, 1989) . Previous studies have demonstrated that CAI but little, if any, CAII is expressed in C19 MEL cells. However, expression of CAII increases during C19 MEL cell differentiation while CAI is downregulated (Tashian, 1989) . During DMSO-induced differentiation, carbonic anhydrase activity is increased in a similar pattern as hemoglobin synthesis (Scher et al., 1977) , suggesting that the ratio of CAI/CAII may affect MEL cell growth and differentiation (Fraser and Curtis, 1987) . Second, the activity of CAI in terms of CO 2 hydration is only about 15% that of CAII. Again, the drastically changing ratio of CAI:CAII during erythroid differentiation suggests that the requirements for these molecules differ at different stages of differentiation. Third, CAII is primarily expressed in mature erythrocytes where it regulates hemoglobin function in response to CO 2 partial pressure, while CAI is mainly expressed in erythroid progenitors prior to expression of hemoglobin and is involved in maintaining intracellular pH. Thus, the fundamental roles of CAI and CAII appear to differ. In addition, CA are now appreciated to mediate chemical reactions beyond hydration of CO 2 and these activities may well differ between CAI and CAII (Pastorekova et al., 2004) . Clearly, it will be important to further define the relative roles of CAI and CAII in regulating erythrocyte differentiation and their contributions to erythroleukemia.
Materials and methods
Cell culture
The C19 MEL cell line is a thymidine kinase-negative subclone of the 745 murine erythroleukemia cell line (McClinton et al., 1990) and was grown in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum and 2 mM glutamine. Clone 17 cells are stable transfectants of the C19 MEL cell line that contain a dominant interfering Myb cDNA (MEnT) under the inducible transcriptional control of a mouse metallothionein I promoter and were cultured in the same medium containing G418 at a concentration of 400 mg/ml (Chen et al., 2002) . CV1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% newborn calf serum and 5% fetal bovine serum. All cell lines were maintained at 371C in a humidified 5% CO 2 chamber.
Differential display C19 MEL cells and the clone 17 cell line were cultured with or without 100 mM ZnCl 2 for the indicated times. Cells were harvested and washed twice with phosphate-buffered saline (PBS) and total cellular RNA was prepared from the cell pellets using RNeasy Mini kits (Qiagen) as per the manufacturer's instructions. For differential display, 50 mg of total cellular RNA from each sample was treated with DNase I for 30 min at 371C to remove residual chromosomal DNA contamination. After phenol/chloroform extraction, the RNA was precipitated with ethanol in the presence of 0.3 M sodium acetate, dissolved in diethyl pyrocarbonate-treated water (DEPC-diH 2 O) and stored as 1 mg aliquots at À801C. RNA was diluted to 0.1 mg/ml with DEPC-diH 2 O just prior to use for differential display analysis. Differential display analysis was performed using the RNAimage kit (Genhunter) as per the manufacturer's instructions. A detailed protocol will be provided upon request.
Northern blot analysis C19 MEL cells and MEnT stable transfectants were cultured with or without HMBA and ZnCl 2 as indicated. Approximately 10 7 cells were harvested at each time point and total cellular RNA was isolated using RNeasy mini kits (Qiagen). Fractionation of RNA and transfer to nitrocellulose membranes was carried out as we have previously described (Bender and Kuehl, 1986) . The following a-[ 32 P]dCTP nicktranslated probes were used: a 294 bp CAI cDNA fragment amplified from C19 MEL cells by RT-PCR (J Chen and TP Bender, unpublished data), a 600 bp BamHI/EcoRI cDNA fragment encoding the murine c-Myb DBD and a 1.2 kb PstI fragment of chicken GAPDH cDNA fragment (44). Quantitation was carried out using a PhosphorImager (Molecular Dynamics) and ImageQuant software.
Reporter and expression plasmids
Cloning of the CAIe promoter and introduction of subsequent mutations were carried out using standard molecular biology techniques and details of each step and sequences of oligonucleotides used for mutagenesis will be provided on request. The mouse CAIe promoter, corresponding to nucleotides À222 through þ 39 (Fraser et al., 1989) , was amplified by PCR from mouse genomic DNA and subcloned into the pTAdv cloning vector (InVitrogen). A series of CAIe promoter deletion mutants, designed to remove potential Myb DNAbinding sites, were created by PCR using a common 3 0 -oligonucleotide primer and a series of nested 5 0 -oligonucleotide primers. The CAIe promoter and each deletion mutant was then subcloned into the BglII site of the pGL2.Basic or pGL3.Basic reporter plasmids (Promega). A further series of mutations in the À222/ þ 39 CAIe promoter, designed to abolish the TATA box deletion, the putative GATA-binding site A and a series of linker scanning mutants were created by oligonucleotide-mediated mutagenesis using the QuickChange site-directed mutagenesis kit (Strategene) and subcloned into the BglII site of pGL2.Basic. The DNA sequence of each CAIe promoter mutant was confirmed prior to use in transient transfection assays.
The pRMB3SV vector was used for expression of wild-type mouse c-Myb protein in transient transfection experiments and has been previously described (Miglarese et al., 1996) . pRMB3SV contains the entire mouse c-myb-coding sequence under the transcriptional control of the Rous Sarcoma Virus long terminal repeat (RSV-LTR) and includes 3 0 -polyadenylation sequences from SV40. The mouse GATA-1 and GATA-2 expression vectors pEF.GATA1 and pEF.GATA2 were gifts from Dr M Yamamoto (University of Tsukuba), and the mouse B-Myb expression vector was the gift of Dr R Watson (Ludwig Institute for Cancer Research).
The coding region of mouse CAIe was amplified by RT-PCR based on the previously published cDNA sequence (Fraser and Curtis, 1986) . The PCR primers each contained a BamHI site for subsequent subcloning and the downstream primer included 30 nucleotides encoding the human 9E10 c-myc epitope tag before the stop codon. The epitope-tagged mouse CAI-coding fragment was initially subcloned into the pT-Adv cloning vector (pTA-CAIe) and the oligonucleotide sequence of the PCR product confirmed by DNA sequencing. pTA-CAIe was digested with BamHI and the 840 bp cDNA fragment encoding the full-length CAI was subcloned into the pMTH.neo expression in the sense orientation (Cuddihy et al., 1993) .
Transient transfection experiments and luciferase assays
Transient transfection experiments in CV-1 and C19 MEL cells were performed using Effectene transfection reagent (Qiagen) as per the manufacturer's instructions and were carried out in six-well plates. CV1 cells were seeded at 2 Â 10 5 cells/well in six-well plates the day before transfection. Nonadherent C19 MEL cells were seeded at 2 Â 10 6 cells/well in six-well plates on the day of transfection. At 48 h after transfection, the cells were lysed and luciferase activity was measured on a Monolight 2010 luminometer (Analytical Luminescence Laboratory) using a commercial luciferase assay kit (PharMingen). Luciferase activity was normalized based on protein concentration as assayed by BCA Protein Assay Reagent (Pierce).
Nuclear extracts and EMSA C19 MEL cell nuclear extracts were prepared as previously described (Latchman, 1993) . Double-stranded oligonucleotides were labeled with [a-32 P]dCTP (3000 mCi/mmol, Amersham) by fill-in reaction using the Klenow fragment of DNA polymerase I. Unincorporated nucleotides were removed from the labeling reactions using the Nucleotide Removal Kit (Qiagen). EMSA were performed as we have previously described (Miglarese et al., 1996) . For super shift experiments, nuclear extracts were preincubated with 1 mg of either anti-GATA-1 (N1, Santa Cruz), anti-human c-Myc epitope 9E10 or the anti-c-Myb DNA-binding domain 5E (gift of Dr Eric Weston, NIH) monoclonal antibodies for 30 min at 41C.
ChIP assay
ChIP assay was performed using the antiacetylated histone H3 antibody-based ChIP assay kit (Upstate Biotech) with slight modifications. Briefly, 37% formaldehyde solution was added directly to exponentially growing C19 MEL cells to a final concentration of 1% and cells were incubated for 10 min at 371C. Cells were harvested and washed twice with ice-cold PBS containing protease inhibitors (Complete, Protease Inhibitor Cocktail Tablet, Roche) and lysed with SDS lysis buffer for 10 min on ice. The lysate was sonicated to an average length of 500-1000 base pairs and clarified by centrifugation at 16 000 g for 10 min at 41C. The samples were then precleared with salmon-sperm DNA-protein A-Agarose beads (Upstate Biotech) for 2 h. After a brief spin, the supernatant fraction was collected and diluted 10-fold with ChIP dilution buffer and split into five equal parts for immunoprecipitation with (1) no antibody, (2) normal rabbit IgG (Santa Cruz, SC-2027), (3) anti-c-Myb (SC-7874), (4) normal rat IgG (SC-2026) and (5) anti-GATA-1 (SC-265). Immunoprecipitation was carried out overnight with rotation at 41C. Beads were harvested, washed, and eluted as per the manufacturer's instructions. Crosslinking was reversed by heating at 651C for 4 h. DNA was purified by phenol-chloroform extraction and recovered by ethanol precipitation. Precipitated DNA was analysed by PCR amplification for 25 cycles (941C for 1 min, 521C for 45 s and 721C for 45 s for CAI and 941C for 1 min, 581C for 45 s, 721C for 45 s for Cyclin G2), separated on 2% agarose gel, transferred to Nylon membranes and hybridized to the specific probes. The primer sets used for PCR are as follows: CAI forward: CGC AAG CTT TTG ATT AAG TCC ACA CC; CAI reverse: CGC AAG CTT TCC AGT AAG TCC CTC CCT GAC. For the ChIP control, PCR primers for Cyclin G2 promoter were provided by Dr David Fruman (University of California, Irvine), Cyclin G2 forward: CAG AGG ACG CAA CAG CCA GTC GG; Ccng2 reverse: CCG CAG CCT CCG GAG CTG AGC. PCR products were resolved by electrophoresis through 3% Nusieve agarose gels and transferred to nylon membranes. Probes were amplified by PCR from the cloned promoters using the same primer set, gel purified using the Qiagen gel extraction kit and radiolabeled by using RadPrime DNA Labeling System (Invitrogen). Hybridization was performed at 421C for 24 h according to the protocol provided by BD Clontech. Filters were exposed to a phosphor screen and visualized by using a phosphorImager system. CAI MEL cell stable transfectants and protein blotting Stable transfections into C19 MEL cells were performed using lipofectin (Invitrogen) as we have previously described in detail (McClinton et al., 1990) . Stable transfectants were cultured in growth medium containing 400 mg/ml G418 in the absence or presence of 100 mM ZnCl 2 for 16 h. Approximately 2 Â 10 7 cells were harvested and sonicated in 1 ml YRIPA lysis buffer as we have previously described (Aziz et al., 1995) , and 100 mg of whole-cell lysates were resolved by sodium dodecylsulfate-10% polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred to nitrocellulose membranes and the membranes were blocked in PBS-0.05% Tween (PBS-T) containing 3% nonfat dried milk and then probed with the 9E10 anti-c-Myc epitope monoclonal antibody followed by horseradish peroxidase (HRP)-linked secondary antibody. After washing with PBS-T, immunoreactive bands were detected by enhanced chemiluminescence (Amersham). To quantify CAI expression, whole-cell lysates were fractionated by SDS-PAGE and transferred to nitrocellulose. The filter was incubated with a polyclonal goat anti-human CAI antiserum (Rockland) followed by incubation with 125 I-labeled protein-G (Amersham). Filters were exposed to Kodak BioMax-MS films with an enhancer screen at À801C for 4-12 h.
Differentiation and proliferation assays
Differentiation of C19 MEL cells and CAI stable transfectants was assayed by acid-benzidine staining to measure hemoglobin-producing cells (Friend et al., 1971) . Briefly, cells were plated at a density of 1 Â 10 5 cells/ml and grown in the absence or presence of 100 mM ZnCl 2 and 3 mM HMBA for 6 days.
Cells were maintained in logarithmic phase by daily 1:1 dilution with fresh medium. At specific time points, cells were removed and stained with acid-benzidine. To measure cell proliferation, each cell line was plated at a density of 1 Â 10 5 cells/ml and grown in the presence of 100 mM ZnCl 2 or 100 mM ZnCl 2 with addition of 3 mM HMBA for 6 days. Cell numbers from each sample were counted at the induced time points and cells were passaged at the original cell density every other day with fresh medium.
